WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H412742
CAS#: 77639-66-8 (free base)
Description: Prinomide is a carbamoylpyrrolepropionitrile derivative patented by Ciba-Geigy A.-G. as a nonsteroidal anti-inflammatory drug that has disease-modifying activity in rheumatoid arthritis. In clinical trials, Prinomide demonstrate significant improvement in symptom score and laboratory variables.
Hodoodo Cat#: H412742
Name: Prinomide
CAS#: 77639-66-8 (free base)
Chemical Formula: C15H13N3O2
Exact Mass: 267.10
Molecular Weight: 267.290
Elemental Analysis: C, 67.40; H, 4.90; N, 15.72; O, 11.97
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 109636-76-2 (tromethamine) 77639-66-8 (free base)
Synonym: Prinomide; CGS10787B; CGS-10787B; CGS 10787B
IUPAC/Chemical Name: 2-cyano-3-(1-methyl-1H-pyrrol-2-yl)-3-oxo-N-phenylpropanamide
InChi Key: KBQUAIAGRLAZGP-UHFFFAOYSA-N
InChi Code: InChI=1S/C15H13N3O2/c1-18-9-5-8-13(18)14(19)12(10-16)15(20)17-11-6-3-2-4-7-11/h2-9,12H,1H3,(H,17,20)
SMILES Code: Cn1c(C(C(C(Nc2ccccc2)=O)C#N)=O)ccc1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 267.29 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Egger H, Itterly W, John V, Rodebaugh R, Shimanskas C, Stancato F, Kapoor A. Disposition and metabolism of prinomide in laboratory animals. Drug Metab Dispos. 1988 Jul-Aug;16(4):568-75. PMID: 2903025.
2: Kochak GM, Pai S, Iannucci R, Honc F, Kachmar D, Perrino P, Egger H. Prinomide tromethamine pharmacokinetics: mutually dependent saturable and competitive protein binding between prinomide and its own metabolite. Pharm Res. 1993 Jan;10(1):49-55. doi: 10.1023/a:1018916811904. PMID: 8430060.
3: Cohick CB, Furst DE, Quagliata S, Corcoran KA, Steere KJ, Yager JG, Lindsley HB. Analysis of elevated serum interleukin-6 levels in rheumatoid arthritis: correlation with erythrocyte sedimentation rate or C-reactive protein. J Lab Clin Med. 1994 May;123(5):721-7. PMID: 8195678.
4: Parrish DD, Schlosser MJ, Kapeghian JC, Traina VM. Activation of CGS 12094 (prinomide metabolite) to 1,4-benzoquinone by myeloperoxidase: implications for human idiosyncratic agranulocytosis. Fundam Appl Toxicol. 1997 Feb;35(2):197-204. doi: 10.1006/faat.1996.2270. PMID: 9038241.
5: Bird HA, Hill J, Dixon JS, Bojar R, Traficante A, Catalano MA, Adair SF, Liauw L, Sussman H, Rotman H, et al. A clinical and biochemical assessment of prinomide in patients with rheumatoid arthritis. J Rheumatol. 1989 Apr;16(4):448-54. PMID: 2664168.
6: Doughty JR, Goldberg RL, Schenkelaars EJ, Singh HN, Peppard J, Haston W, Blancuzzi VJ, Di Pasquale G. Relationship of blood markers to disease severity and drug efficacy in rat adjuvant arthritis. Agents Actions. 1991 Sep;34(1-2):129-31. doi: 10.1007/BF01993257. PMID: 1793016.
7: Schenkelaars EJ, Singh HN, Goldberg RL, Doughty JR, Peppard J, DiPasquale G, Quagliata F. Pharmacological modulation of rat monocytes: in vivo effects on Ia expression and interleukin-1 production. Agents Actions. 1991 Sep;34(1-2):66-9. doi: 10.1007/BF01993240. PMID: 1793054.
8: Akita S, Abe C, Hirose S. Effect of a new antirheumatic drug (CGS10787B) on antibody formation and delayed-type hypersensitivity in BALB/c mice. Int J Tissue React. 1988;10(4):199-205. PMID: 3266939.
9: Luders RC, Brunner LA. Automated sample preparation and chromatographic analysis: determination of CGS 10787B and related compounds. J Chromatogr Sci. 1987 May;25(5):192-7. doi: 10.1093/chromsci/25.5.192. PMID: 3597649.
